Welcome to AiCuris: The Powerhouse for Anti-infectives    


“Committed to making the difference”

AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).

Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.





BEAT-COV: Entwicklung COVID-19-Medikamente

Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente
  • Sichere und hoch wirksame Medikamente sind dringend erforderlich, um COVID-19-Patienten zu versorgen und Krankenhäuser zu entlasten.
  • Impfstoffe schützen vor Erkrankung, aber bereits Erkrankte benötigen dringend Medikamente für eine gezielte Therapie von Symptomen und eine Verbesserung der Überlebenschancen. Es fehlt die zielgerichtete Förderung von in der Entwicklung bereits fortgeschrittenen Medikamenten zur Behandlung von COVID-19.
  • BEAT-COV (Biotech Emergency Alliance for Therapies against COVID-19) ist ein Zusammen­schluss von vier deutschen, mittelständischen Biotechnologieunternehmen mit erfolg­versprechenden COVID-19-Therapieansätzen in späten Phasen der klinischen Entwicklung.

Read more ...

Compassionate Use Program for Pritelivir

AiCuris receives approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany
  • The Compassionate Use Program (CUP) may provide access to pritelivir for use in immunocompromised patients that have acyclovir-resistant mucocutaneous herpes simplex virus infections and foscarnet resistance or intolerance
  • CUPs offer a method to provide patients suffering from an unmet medical need and with no further treatment options with possible access to medication currently not approved in their home country
  • The today announced approval is part of an Early Access Program (EAP) for Pritelivir in various countries throughout the world

Read more ...

AiCuris launches “PREP"

AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference
  • PREP is a comprephensive four-pillar program to help prevent future pandemics and combat antimicrobial resistance (AMR)
    • Exploring opportunities of AiCuris pipeline products to treat Corona; clinical trial with first drug candidate AIC649 with the potential to become a first-line pandemic therapy under preparation
    • Company commits to driving drug development in resistance breaking antibiotics based on novel scientific approaches
    • AiCuris initiates “AiCubator”, providing long-term support for early but promising research projects in the field of anti-infectives
    • Pursuit of an active licensing strategy for pre-clinical and early clinical projects in the anti-infective space to expand the Company’s portfolio
  • AiCuris to participate in several AMR panels and to discuss partnering opportunities at upcoming virtual 4th AMR Conference

Read more ...